France Launches Therapeutic Cannabis Trial with Six International Suppliers
France's therapeutic cannabis trial will treat 3,000 patients with products from six international suppliers, marking a pivotal step in validating cannabis-based treatments
Key Points
- 1France's cannabis trial to treat 3,000 patients begins in March
- 2Six international companies selected as suppliers; no French producers involved
- 3Aurora and Tilray, Canadian firms, secured primary supply roles
- 4Emmac, a UK company, partnered with Boiron as a backup supplier
- 5The trial aims to validate the prescription and distribution of cannabis treatments
France is set to embark on a significant therapeutic cannabis trial starting in March, allowing 3,000 patients to receive cannabis-based treatments. This initiative aims to validate the prescription and distribution process of these treatments. The French National Agency for the Safety of Medicines and Health Products (ANSM) has revealed the list of companies selected to supply cannabis products free of charge during the trial
The bidding process involved twelve lots categorized by THC/CBD content and form. Ultimately, nine lots were awarded, each with a primary supplier and a backup. Six companies secured a primary lot, while five were chosen as backups. Notably, no French producers were selected, highlighting the international nature of the suppliers involved
Canadian company Aurora emerged as a major player, winning three primary lots for THC-dominant, balanced THC/CBD, and CBD-dominant flowers. Despite financial struggles, Aurora's selection positions it favorably for potential future legalization of therapeutic cannabis in France. Hélène Moore, Aurora France's General Manager, expressed enthusiasm about the opportunity to provide their products to French patients
Tilray, another Canadian company, will supply THC-dominant and balanced THC/CBD oils. Other notable suppliers include Israeli company Panaxia and Australian firms Little Green Pharma and Althea. Emmac, a UK-based company, was selected as a backup supplier and partnered with Boiron, a French homeopathy specialist, to strengthen their bid
The trial represents a crucial step in integrating therapeutic cannabis into France's healthcare system. It also underscores the challenges faced by domestic producers in meeting stringent regulatory requirements. Looking ahead, the outcome of this trial could pave the way for broader acceptance and potential legalization of cannabis-based treatments in France